We intend to carry out a comprehensive study of the use of the term λέξις in the rhetorical writings of Dionysius of Halicarnassus. We will investigate its different meanings and interconnections ...with λόγος As we will see, λέξις is still Dionysiuś preferred term when denotingexpressionorstyle, and, thus, he indicates an intermediate stage of evolution between that of Philodemus of Gadara and that of Ps. Longinus or Hermogenes: the latter in these cases have resorted to using λόγος, a non-marked term of opposition, something which would still have been unthinkable for Dionysius.
We intend to carry out a comprehensive study of the use of the term λέξις in the rhetorical writings of Dionysius of Halicarnassus. We will investigate its different meanings and interconnections ...with λόγος. As we will see, λέξις is still Dionysius’ preferred term when denoting expression or style, and, thus, he indicates an intermediate stage of evolution between that of Philodemus of Gadara and that of Ps. Longinus or Hermogenes: the latter in these cases have resorted to using λόγος, a non-marked term of opposition, something which would still have been unthinkable for Dionysius.
Se ha achacado tradicionalmente a Hermógenes de Tarso (161 d.C.) el haber meramente epitomizado el tratado sobre las στάσεις de Hermágoras de Temnos (150 a.C.). Tras analizar la acepción que se ha ...presupuesto hasta la fecha -en nuestra opinión de forma inexacta- para el término στάσις, estudiaremos detalladamente las influencias ejercidas sobre el sistema de Hermógenes y las innovaciones que presenta.
Hermogenes of Tarsus (161 AD) has been traditionally supposed to have merely epitomized the treatise on ... by Hermagoras of Temnos (150 BC). In this paper we analyze the previously alleged meaning ...-in our view inaccurately- of the word ... and we study in detail the influences on Hermogenes' system and the innovations it presents.
Nuestro propósito es analizar los Acta Pauli et Petri apocrypha en lengua griega desde los puntos de vista gramatical y léxico. Dividimos nuestro estudio en dos partes principales: la primera está ...dedicada a la fonética, la morfología, la sintaxis, el orden de palabras y el estilo y la segunda al léxico. También realizamos una comparación de los escritos mencionados con otros no literarios (papiros, inscripciones, ...) o literarios, así como con algunos más correspondientes a niveles de lengua distintos, relativamente contemporáneos o que se pueden incluir en una tradición común (Nuevo Testamento, novelas griegas, etc.).
Our aim is to analyse the Greek Acta Pauli et Petri apocrypha from a grammatical and lexical point of view. We divide our study in two main parts: the first one devoted to phonetics, morphology, syntax, word order and stylistics, the second one dealing with lexical uses. We also compare the texts mentioned above to non-literary (papyri, inscriptions, ...) or literary works, as well as to different stages of language, relatively contemporary or included in a common tradition (New Testament, Greek novels, etc.).
Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment. The objective of this study is to analyze ...whether the use of tocilizumab is associated with respiratory improvement and a shorter time to discharge in patients with COVID-19 and lung involvement.
Observational study on a cohort of 418 patients, admitted to three county hospitals in Catalonia (Spain). Patients admitted consecutively were included and followed until discharge or up to 30 days of admission. A sub-cohort of patients treated with tocilizumab and a sub-cohort of control patients were identified, matched by a large number of risk factors and clinical variables. Sub-cohorts were also matched by the number of other treatments for COVID-19 that patients received. Increment in SAFI (inspired oxygen fraction / saturation) 48 h after the start of treatment, and time to discharge, were the primary outcomes. Mortality, which was a secondary outcome, was analyzed in the total cohort, by using logistic regression models, adjusted by confounders.
There were 96 patients treated with tocilizumab. Of them, 22 patients could be matched with an equivalent number of control patients. The increment in SAFI from baseline to 48 h of treatment, was not significantly different between groups (tocilizumab: −0.04; control: 0.09; p = 0.636). Also, no difference in time to discharge was found between the two sub-cohorts (logrank test: p = 0.472). The logistic regression models, did not show an effect of tocilizumab on mortality (OR 0.99; p = 0.990).
We did not find a clinical benefit associated with the use tocilizumab, in terms of respiratory function at 48 h of treatment, or time to discharge.
PDF
